Skip to Content

Tag Archives: Congress

November 2008 Issue & Supplement

Has Murphy’s Law taken over the economy and stock market? In recent weeks, it seems that just about everything that could go wrong, has. Retail sales and industrial output are skidding while unemployment and foreclosures surge. Even the passage (after much dickering) of a $700 billion financial “stabilization” program by Congress proved unable to stop a waterfall plunge in stock prices.

Grim tidings, these. As investors, though, we know that the important question, always, is: What happens next? Will conditions get better–or much worse?

In this month’s visit, I’ll help you understand the odds. I’ll also show you how to profit from the inevitable recovery when it comes, while protecting yourself in case Wall Street continues to stumble longer than any of us hopes.

November 2008 Issue & Supplement

Has Murphy’s Law taken over the economy and stock market? In recent weeks, it seems that just about everything that could go wrong, has. Retail sales and industrial output are skidding while unemployment and foreclosures surge. Even the passage (after much dickering) of a $700 billion financial “stabilization” program by Congress proved unable to stop a waterfall plunge in stock prices.

Grim tidings, these. As investors, though, we know that the important question, always, is: What happens next? Will conditions get better–or much worse?

In this month’s visit, I’ll help you understand the odds. I’ll also show you how to profit from the inevitable recovery when it comes, while protecting yourself in case Wall Street continues to stumble longer than any of us hopes.

April 2008 Issue

The mercury is climbing, blossoms are bursting out — so does Wall Street finally get to celebrate a springtime of its own? For eight long months now, a ferocious credit crunch, unprecedented since the Great Depression, has trapped investors in a deep freeze. Not only stocks and real estate, but even some of the (reputedly) safest bonds and money market instruments fell victim to the Arctic blast.

Happily, I’m detecting hints, here and there, of a thaw. It’s taking a lot longer than I had hoped, but we will see the end of this new Ice Age. As a balmier climate sets in, we can look forward to healthy markets again — and a return to the steady, consistent profits we enjoyed from 2003 to around mid-2007.

December 2006 Issue

Gridlock! Whether you’re delighted or dismayed by the results of the midterm election, I’ve got encouraging news for you—a divided government in Washington isn’t such a bad thing for your investments. This month, I’ll show you how you can take advantage of the new paths to profit that the election has opened up. In fact, I expect gains of 40%-60% in the next two years for my top picks. December also marks the fourth anniversary of our Incredible Dividend Machine. This nifty portfolio has beaten the overall stock market by such a huge margin it’s almost amusing. In our latest lineup, I’m swapping two of the members of the Machine with new names that I’m confident will keep the streak going. Finally, the holiday season is the perfect time to do some housecleaning, and if you’re sitting on a mutual fund that has outlived its usefulness, raise a glass of holiday cheer and toast it good-bye. Then replace it with one of my four best funds for your specific needs.

Cyclical Surprise

The stock market can do almost anything it wants, anytime. If you needed proof of this bedrock principle, the past quarter’s trading should lay any doubts to rest. Assuming no disaster occurs tomorrow, we’ll close September with the strongest quarterly percentage gain on the S&P 500 since 2004.

Narrow but Clear

Last night’s election results have sent the message the stock market wanted to hear. President Bush has won a second term by a narrow, but clear margin. The GOP has held on to both houses of Congress, and looks to have increased its lead significantly in the Senate. What does it mean for investors?

ANYBODY FOR DRUGS?

In the midst of this new bull market, one group of stocks is writhing in pain: pharmaceuticals. Are we hearing a death knell — or is it a dinner bell?

I’m inclined to press the button for Option #2. Granted, all the major drug makers are facing issues with patent expirations in the next couple of years.